Difluorocarbene radiosynthesis
US-2024383827-A1 · Nov 21, 2024 · US
Selective androgen receptor modulator and methods of use thereof
US10662148B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10662148-B2 |
| Application number | US-201815887076-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 2, 2018 |
| Priority date | Jun 7, 2004 |
| Publication date | May 26, 2020 |
| Grant date | May 26, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating, reducing the severity, reducing the incidence, or reducing cardiovascular failure in a subject suffering from Duchenne muscular dystrophy, comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound represented by the structure of formula S-(III): or its pharmaceutically acceptable salt. 2. The method of claim 1 , wherein said method further increases the physical function of said subject. 3. The method of claim 1 , wherein said method further increases the quality of life of said subject. 4. The method of claim 1 , wherein said method increases the survival of said subject. 5. The method of claim 1 , wherein said method further delays onset or improves symptoms of respiratory function.
Assignees
Inventors
Classifications
- C07C255/54Primary
containing cyano groups and etherified hydroxy groups bound to the carbon skeleton · CPC title
- A61K31/277Primary
having a ring, e.g. verapamil · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10662148B2 cover?
- This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.
- Who is the assignee on this patent?
- Univ Tennessee Res Found
- What technology area does this patent fall under?
- Primary CPC classification C07C255/54. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).